60
Participants
Start Date
February 9, 2021
Primary Completion Date
November 30, 2025
Study Completion Date
November 30, 2025
Patient with histologically confirmed diffuse large B-cell lymphoma with a planned first line treatment by R-CHOP.
"Blood samples will be collected :~* at baseline (before the 1st R-CHOP cycle)~* before the 3d administration of chemotherapy (CT) (i.e. after 2 cycles of CT and same timepoint as interim FDG-PET/CT)~* after the 4th administration of the CT~* at the end of induction (i.e. end of R-CHOP treatment)~* at 24 months after initiation of R-CHOP treatment~* at the time of progression (if progression occurs before 24 months of treatment).~Tumor samples will be collected at baseline (from an archived initial diagnostic tumor specimen) and at the time of progression (if applicable from lymph node biopsy performed as part of a standard of care surgical procedure).~Bone marrow samples will be collected at baseline and at the time of progression (if applicable) only in patients for whom a bone marrow aspiration (BMA) is necessary as part of their standard of care, upon physician's decision."
Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse
Collaborators (1)
AstraZeneca
INDUSTRY
Institut Claudius Regaud
OTHER